NeoGenomics

NEO

Market cap $1.57B

Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.

NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.

NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025.

NeoGenomics NEO is in Phase 18, the final stage of its Adhishthana Cycle on the weekly charts. After more than 850 days of consolidation, the stock shows little sign of breaking out.